Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer

Figure 5

Vaccination-associated predominating antigen expressions and effects of ROR1 knockdown on immunogenicity of CSC vaccination. (a) The mRNA expressions of ROR-1, MUC-1, and NY-ESO-1 in HO8910 CSCs and HO8910 non-CSCs detected by qRT-PCR. (b) ROR-1 expression in the different cells detected by qRT-PCR. (c–g) ROR-1 expression in the different cells analyzed by Western blotting and quantification of analysis. (h) Serum IFN-γ level in shROR1 HO8910 CSC-vaccinated mice. (i) Anti-ROR1 antibody level in the shROR1 HO8910 CSC-vaccinated mice (serum 1 : 320 dilution). (j) Serum TGF-β1 level in shROR1 HO8910 CSC-vaccinated mice. (k) Serum IFN-γ level in shROR1 ID8 sphere-vaccinated mice. (l) Anti-ROR1 antibody level in the shROR1 ID8 sphere-vaccinated mice (serum 1 : 160 dilution). (m) Serum TGF-β1 level in shROR1 ID8 sphere-vaccinated mice. (n) NK cytotoxicity in shROR1-ID8 sphere-vaccinated mice. (o) Quantification of NK cytotoxicity. (p) Splenocyte cytotoxicity in shROR1-ID8 sphere-vaccinated mice. (q) Quantification of splenocyte cytotoxicity. (r) CDC activity in shROR1-ID8 sphere-vaccinated mice. (s) Quantification of CDC activity. Statistically significant differences between the different groups were indicated.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)

(r)

(s)